Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vita Life SciencesASX:VLS 96 Intrinsic Value: Projected FCF is A$2.71 as of Aug. 11, 2026, which is 100% below its 10-year median of 0.92. GuruFocus rates ASX:VLS with a GF Score™ of 96/100 and a GF Value™ of A$2.50 (Fairly Valued). The stock has 1 warning sign investors should review. Among 630 Drug Manufacturers companies, Vita Life Sciences ranks better than 72.86% on this metric.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
As of today (2026-08-11), Vita Life Sciences's Intrinsic Value: Projected FCF is A$2.71. The stock price of Vita Life Sciences is A$2.50. Therefore, Vita Life Sciences's Price-to-Intrinsic-Value-Projected-FCF of today is 0.9.
The historical rank and industry rank for Vita Life Sciences's Intrinsic Value: Projected FCF or its related term are showing as below:
ASX:VLS'
s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 0.69 Med: 0.92 Max: 1.39
Current: 0.92
During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Vita Life Sciences was 1.39. The lowest was 0.69. And the median was 0.92.
ASX:VLS's Price-to-Projected-FCF is ranked better than 72.86% of 630
companies
in the Drug Manufacturers industry
Industry Median: 1.57
vs ASX:VLS: 0.92
Vita Life Sciences (ASX:VLS) Intrinsic Value: Projected FCF Explanation
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
Vita Life Sciences's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF
=
Share Price
/
Intrinsic Value: Projected FCF
=
2.50
/
2.7108333476651
=
0.92
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vita Life Sciences Intrinsic Value: Projected FCF Related Terms
Vita Life Sciences Intrinsic Value: Projected FCF Historical Data
* Premium members only.
The historical data trend for Vita Life Sciences's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vita Life Sciences Intrinsic Value: Projected FCF Chart
ASX:VLS vs ZTS: Intrinsic Value: Projected FCF Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vita Life Sciences's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vita Life Sciences Price-to-Projected-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vita Life Sciences's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where Vita Life Sciences's Price-to-Projected-FCF falls into.
Vita Life Sciences Intrinsic Value: Projected FCF Calculation
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Intrinsic Value: Projected FCF of A$2.71 mean?
Vita Life Sciences (ASX:VLS) has a Intrinsic Value: Projected FCF of A$2.71 as of Aug. 11, 2026. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Vita Life Sciences and its competitors. This is 195% above median its historical median of 0.92. Over the past decade, Vita Life Sciences' Intrinsic Value: Projected FCF has ranged from 0.69 to 1.39. According to the industry distribution chart, Vita Life Sciences ranks #171 out of 630 companies in the Drug Manufacturers industry, placing it in the top 27.1%.
Is Vita Life Sciences' Intrinsic Value: Projected FCF too high?
Vita Life Sciences' current Intrinsic Value: Projected FCF of A$2.71 is 195% above median its 10-year median of 0.92. Over the past 10 years, this metric has ranged from a low of 0.69 to a high of 1.39. Based on the distribution chart, Vita Life Sciences ranks #171 out of 630 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Vita Life Sciences has a GF Score™ of 96/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vita Life Sciences' Intrinsic Value: Projected FCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vita Life Sciences ranks #171 out of 630 companies for Intrinsic Value: Projected FCF. This puts Vita Life Sciences in the upper half of its industry. The industry median Intrinsic Value: Projected FCF is 1.57. Historically, Vita Life Sciences' own Intrinsic Value: Projected FCF has ranged from 0.69 to 1.39 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intrinsic Value: Projected FCF for a Drug Manufacturers company?
The median Intrinsic Value: Projected FCF among Drug Manufacturers companies is 1.57, based on 630 companies in the industry. Companies in the top quartile (top 25%) have a Intrinsic Value: Projected FCF significantly above this median, while those in the bottom quartile fall well below. However, Intrinsic Value: Projected FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intrinsic Value: Projected FCF mean?
A high Intrinsic Value: Projected FCF can signal that a stock is expensive relative to its fundamentals. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Vita Life Sciences and its competitors. For the Drug Manufacturers industry, the median Intrinsic Value: Projected FCF is 1.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vita Life Sciences's current Intrinsic Value: Projected FCF is A$2.71, which is 195% above median its own 10-year median of 0.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vita Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Vita Life Sciences (ASX:VLS) is currently considered Fairly Valued. The stock's GF Value™ is A$2.50, compared to a current price of A$2.50 — trading right at its estimated fair value. The current Intrinsic Value: Projected FCF is A$2.71, which is 195% above median its 10-year median of 0.92. Vita Life Sciences' overall GF Score™ is 96/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intrinsic Value: Projected FCF calculated?
Intrinsic Value: Projected FCF is calculated from a company's financial statements. For Vita Life Sciences (ASX:VLS), the current Intrinsic Value: Projected FCF is A$2.71 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vita Life Sciences (ASX:VLS) Overvalued in 2026?
Based on GuruFocus' analysis, Vita Life Sciences stock appears to be undervalued.
The current stock price of A$2.50 is trading 0% below its estimated GF Value™ of A$2.50.
GuruFocus considers Vita Life Sciences to be Fairly Valued.
Key valuation signals for ASX:VLS:
Intrinsic Value: Projected FCF: A$2.71 (195% above median its 10-year median of 0.92)
GF Value™: A$2.50 vs. price of A$2.50 (0% below fair value)
No single metric tells the full story. See the ASX:VLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vita Life Sciences Ltd is an Australian-based pharmaceutical and healthcare company involved in formulating, packaging, selling, and distributing vitamins and supplements. It produces a wide range of premium supplements, vitamins, minerals, herbs, and superfoods catered to all age categories and health conditions. The company markets its products through pharmacies and health food stores under the VitaHealth, VitaScience, and Herbs of Gold brands throughout the Asia-Pacific region. Vita Life Sciences has two operating segments: VMS Operational, which generates maximum revenue, and VMS Investments. Geographically, the Group generates maximum revenue from Malaysia and Singapore, and the rest from Australia, and China and Vietnam.
96GF Score
Get the complete analysis for ASX:VLS
Intrinsic Value: Projected FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:VLS has been successfully added to your 
